Perrigo to Release Third Quarter 2026 Financial Results on November 4, 2026

Perrigo plans to release its third-quarter 2026 financial results on November 4, 2026, followed by a conference call at 8:30 a.m. ET hosted by Interim CEO Albert Manzone and CFO Eduardo Bezerra. The announcement provides no results or financial outlook.

Analysis

This is a calendar notice, not a change in fundamentals; it does not support a directional PRGO position. The relevant setup is the November 4 report: an interim CEO makes management’s framing of execution and the path to permanent leadership potentially more price-sensitive, but the notice provides no new operating evidence. The main risk is a gap on results or guidance, not a catalyst created by today’s announcement. Any read-through to Kenvue or Haleon is likely limited unless Perrigo identifies a broader OTC/self-care demand, pricing, or channel trend. Near term, check consensus expectations, recent guidance, and available options pricing before treating the event as mispriced. Over 1–3 months, a credible update on operating trends and leadership succession could reduce uncertainty; absent that, the announcement alone should not alter a 6–18 month view. The watch thesis is falsified by a material guidance change or operating deterioration/improvement that is confirmed in reported results, rather than by the earnings-date notice itself.

Key Decisions for Investors

• No trade on the announcement; avoid inferring a fundamental inflection from routine earnings logistics.
• Ahead of November 4, monitor PRGO guidance and the earnings-call discussion of operating performance and leadership succession; verify consensus estimates and implied event volatility before considering an event position.
• Reassess only if reported results or guidance materially change the earnings trajectory. Treat peer read-through to Kenvue and Haleon as conditional on evidence of shared category or channel trends.